Table 2 Characteristics of included studies.
| Reference |
Design* |
Condition† |
Sample size |
Mean age (SD) |
PrD‡ |
F§ (Hz) |
D|| (min) |
Control |
| Neurological conditions |
| Ahlborg et al. (2006)** |
RCT |
CP |
14 |
31.2 (6.0) |
L |
25-40 |
6 |
Ex |
| Arias et al. (2009)† † |
P-RCT |
PD |
21 |
66.7 (8.4) |
L |
6 |
10 |
Placebo |
| Broekmans et al. (2010)** |
RCT |
MS |
25 |
47.9 (1.9) |
L |
25-45 |
2.5 |
Rest |
| Brogardh et al. (2010)** |
Q-Ex |
Polio |
5 |
64.0 (6.7) |
L |
25 |
3.75 |
No C |
| Ebersbach et al. (2008)† † |
RCT |
PD |
21 |
73.8 (6.1) |
L |
25 |
15 |
PT |
| Haas et al. (2006a)‡‡ |
RCT |
PD |
68 |
65.0 (7.8) |
A |
6±1 |
5 |
Rest |
| Haas et al. (2006b)‡‡ |
P-RCT |
PD |
28 |
63.1 (7.3) |
A |
6±1 |
5 |
Rest |
| Jackson et al. (2008)† † |
RCT |
MS |
15 |
54.6 (9.6) |
A |
2/26 |
0.5 |
No C |
| Ness et al. (2009)** |
Q-Ex |
SCI |
17 |
47.6 (10.2) |
L |
50 |
2-4 |
No C |
| Schuhfried et al. (2005)‡‡ |
RCT |
MS |
12 |
47.7 (12.5) |
A |
2-4.4 |
5 |
TENS |
| Schyns et al. (2009)** |
RCT |
MS |
16 |
47.7 (7.4) |
L |
40 |
0.5 |
No C |
| Tihanyi et al. (2007)** |
RCT |
ST |
16 |
58.2 (9.4) |
A |
20 |
6 |
Ex |
| Turbanski et al. (2005)‡‡ |
P-RCT |
PD |
52 |
69.1 (8.9) |
A |
6±1 |
5 |
Rest |
| Van Nes et al. (2004)† † |
P-RCT |
ST/H |
46 |
61.2 (10.3) |
A |
30 |
7 |
WBV |
| Van Nes et al. (2006)† † |
RCT |
ST |
53 |
58.1 (11.4) |
L |
30 |
3 |
Ex |
| Musculoskeletal conditions |
| Alentorn-Geli et al. (2008)** |
RCT |
FM |
24 |
55.0 (3.0) |
L |
30 |
4.5-18 |
Ex |
| Alentorn-Geli et al. (2009)** |
RCT |
FM |
33 |
56.9 (3.3) |
L |
30 |
4.5-18 |
Rest |
| Gusi et al. (2010)† † |
RCT |
FM |
41 |
52.7 (11.3) |
L |
12.5 |
6-12 |
Rest |
| Johnson et al. (2010)** |
RCT |
TKA |
16 |
67.8 (8.0) |
L |
35 |
2-18 |
Ex |
| Moezy et al. (2008)** |
RCT |
ACLS |
20 |
23.6 (3.7) |
L |
30-50 |
4-16 |
PT |
| Rittweger et al. (2002)† † |
RCT |
LBP |
50 |
51.7 (5.8) |
L |
18 |
4-7 |
Ex |
| Trans et al. (2009)§§ |
RCT |
OA |
52 |
60.4 (9.6) |
L |
25-30 |
3-10 |
Rest |
| Metabolic conditions |
| Baum et al. (2007)** |
RCT |
D |
40 |
62.7 (5.7) |
L |
30-35 |
4 |
FL/ST |
| Iwamoto et al (2005)† † |
RCT |
OP |
50 |
71.3 (8.3) |
L |
20 |
4 |
Rest |
| Rietschel et al. (2008)† † |
Q-Ex |
CF |
10 |
35.2 (8.3) |
L |
20-25 |
9 |
No C |
| Roth et al. (2008)† † |
Q-Ex |
CF |
8 |
33.0 (6.6) |
L |
12 |
6 |
No C |
Designs: Randomised-controled trial (RCT); Pseudo- RCT (P-RCT); Quasi-Experimental (Q-Ex) Conditions: Celebral Parsy (CP); Parkinson’s Disease (PD); Multiple Sclerosis (MS); Poliomyelitis (Polio); Spinal Cord Injury (SCI); Stroke (ST); Healthy (H); Fybromyalgia (FM); (TKA); Anterior Crutiate Ligament Surgury (ACLS); Low-back pain (LBP); Diabetes (D); Osteoporosis (OP); Cystic Fybrosis (CF); Osteoarthritis (OA) Program Duration (PrD): Long-term (L); Acute (A) Frequency (F) Duration (D) Conrol group(s): Exercise (Ex); No control (No C); Physiotherapy (PT); whole-body vibration (WBV); Flexibility (FL); Strengthening (ST) Platforms using l simultaneous vertical WBV Platforms using side-to-side alternating vertical WBVPlatforms using multidirectional WBVUnidentified WBV platform type
